Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

Leerink Partners analyst Asthika Goonewardene has initiated coverage of Zentalis Pharmaceuticals (NASDAQ: ZNTL) with an Outperform rating. The firm has also raised its price target for the stock to $8.